Andre Goy, MD, discusses how progress in immunotherapy and precision medicine at ASH 2024 is offering transformative insights, with JTCC highlighting the latest tumor-targeted therapies and biomarker-driven treatments that are shaping the future of personalized cancer care and improving patient outcomes.
Andre Goy, MD, discusses how progress in immunotherapy and precision medicine at ASH 2024 is shaping the future of cancer treatment, with key insights from the JTCC highlighting emerging therapies and their potential to improve patient outcomes through personalized approaches.
